Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024




Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Enables the Simultaneous Measurement of 64 Molecular Interactions

BOSTON–(BUSINESS WIRE)–$BRKR #BRKR–At the SLAS2024 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘TriceratopsSPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality. In modern drug discovery, SPR is indispensable for the real-time, label-free biophysical characterization of molecular interactions.




The ‘Triceratops’ SPR #64 system combines highest sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the 8-channel flow cell, now facilitates the simultaneous reading of 64 sensor spots. This ingenious design extends SPR capabilities beyond previous limits, accelerating screening, kinetics, epitope characterization, condition scouting, concentration analysis, and thermodynamics. With the ‘Triceratops’ SPR #64, Bruker is now offering drug discovery customers the highest throughput in the industry with uncompromising data quality.

Immediate SPR #64 access and visual controls are facilitated through a built-in touchscreen. Automation features, including integration of any external robot, as well as the direct control via its API, mark a new milestone in convenient SPR-based biopharma research. The SPR #64 software integrates high performance, flexibility, and ease of use throughout every stage, from acquisition to final reports. Each module is intuitively designed, offering guidance for key applications such as SPR affinity and kinetics determination, thermodynamics, and epitope characterization.

David Myszka, Ph.D., Director at Biosensor Tools LLC in Salt Lake City, Utah, commented: “I was thrilled to collaborate with Bruker’s engineers on the design of the new SPR #64 instrument. The ‘Triceratops’ system offers an awesome combination of flexibility, sensitivity, and throughput. The days of tediously testing coupling chemistries and surface density are long gone. With 8 independent channels, we can test a range of conditions at the same time to find the optimum condition in one run. Imagine how content Goldilocks would be getting data from a single experiment ‘that was just right’!”

Dr. Martin Kleinschmidt, Group Leader Bioanalytics in the Department of Drug Design and Target Validation at the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, said: “In collaboration with Bruker, I have tested their new SPR #64 instrument. We successfully measured over 1000 antibody-containing samples against eight different targets, achieving consistent data in less time than with previous SPR measurements. The new ‘Triceratops’ SPR #64 system offers a very useful increase in throughput.”

Dr. Meike Hamester, VP Label-Free Biopharma Technologies at Bruker Daltonics, concluded: “The ‘Triceratops’ SPR #64, our exciting new high-end SPR system for drug discovery, is nicely complemented by Bruker’s SPR-24 Pro and SPR-32 Pro systems to meet any throughput requirement.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward

Sr. Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Media Contact:
Petra Scheffer

Marketing Communications

Bruker Daltonics

T: +49 (421) 2205-2843

E: petra.scheffer@bruker.com